Nimble Therapeutics and Genentech, a member of the Roche Group, have expanded their partnership, the company announced today.

According to a release, the companies executed a license agreement for the discovery of peptide therapies for the treatment of diseases across multiple therapeutic areas.

“We are excited to significantly expand our partnership and strengthen our collaboration with Genentech,” Nimble Therapeutics Founder and CEO Jigar Patel said in a statement. “Genentech has been a valuable strategic partner and we are proud that our success thus far has led to the opportunity to significantly broaden our work together with both Genentech and Roche.”

Nimble will receive a $20 million upfront payment, plus near-term, preclinical, clinical and commercial milestone payments that could exceed $1.1 billion, as well as tiered royalty payments. It will apply its platform against multiple targets, and Genentech/Roche will be responsible for the preclinical and clinical development and commercialization of any resulting products.